Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial

The ITACa trial was designed to define the role of cetuximab (Cet) and bevacizumab (Bev) in combination with standard chemotherapy (CT, FOLFIRI or FOLFOX4) as first- and second-line treatment in metastatic colorectal cancer. All patients with WT KRAS tumors who had been enrolled in the first-line tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Passardi, Alessandro, Scarpi, Emanuela, Gelsomino, Fabio, Palladino, Maria Angela, Casadei Gardini, Andrea, Turci, Daniele, Chiuri, Vincenzo Emanuele, Mucciarini, Claudia, Tassinari, Davide, Ragazzini, Angela, Frassineti, Giovanni Luca, Valgiusti, Martina, Ulivi, Paola, Amadori, Dino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585399/
https://www.ncbi.nlm.nih.gov/pubmed/28874797
http://dx.doi.org/10.1038/s41598-017-11048-9

Ejemplares similares

Ejemplares similares